Provided by the Ig National Society, Inc.
Original Release Date: January 13, 2026
Expiration Date: January 13, 2028
Target Audience
This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients in need of immunoglobulin therapy and specialty biologics.
Educational Objectives
Upon completion of this activity, participants should be able to:
- Differentiate between IVIg and SCIg products and describe how formulation differences influence infusion strategies, tolerability, and clinical decision-making
- Apply current evidence and best practices in the use of Ig therapy for neuromuscular disorders and primary immunodeficiencies, including patient selection and individualized dosing approaches
- Implement Ig administration standards for both IVIg and SCIg in accordance with national guidelines, infusion protocols, and safety monitoring requirements
- Identify key safety risks and mitigation strategies related to Ig therapy, including boxed warnings, IV access considerations, and emerging clinical issues impacting interprofessional practice
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Immunoglobulin National Society (IgNS). IgNS is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
IgNS designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 5.25 contact hours.
Pharmacy Continuing Education
IgNS designates this continuing education activity for 5.25 contact hour(s) (5.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008390-0000-26-004-H99-P)
Type of Activity: Knowledge
Faculty & Disclosures
IgNS requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to IgNS policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty
| Faculty | Conflicts of Interest |
| Leslie Myers, PharmD, IgCP® Integrated Clinical Services Manager |
Has no relevant financial relationships |
| Lucas Felipe Bastos Horta, MD Emory School of Medicine |
Has no relevant financial relationships |
| Elena Perez, MD, PhD Allergist & Immunologist |
Consultant/Advisor/Speaker: ADMA, CSL Behring, Grifols |
| Amy Clarke, DNP, RN, IgCN® Chief Clinical Officer |
Has no relevant financial relationships |
| Christie Fisher, MSN, MBA, RN, CRNI, IgCN® National Director, Nursing |
Has no relevant financial relationships |
| Amy Ehlers, BS, PharmD, CSP, IgCP® Vice President, Clinical Programs |
Consultant/Advisor/Speaker: Octapharma |
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
Participation in this self-study activity should be completed in 5 hours. To successfully complete activities and receive CE credit, learners must follow these steps:
- Review the objectives and disclosures.
- Study the educational content.
- Complete the activity evaluation.
- Upon completion of all evaluation questions your credit will be made available for download immediately.
For Pharmacists: Upon successfully completing the evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.